Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccination

Background: SARS-CoV-2 vaccination in cancer patients is crucial to prevent severe COVID-19 disease course. Methods: This study assessed immunogenicity of cancer patients on active treatment receiving mRNA-based SARS-CoV-2 vaccine by detection of anti-SARS-CoV-2 S1 IgG antibodies in serum, before, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Janzic, Urska, Bidovec-Stojkovic, Urska, Mohorcic, Katja, Mrak, Loredana, Dovnik, Nina Fokter, Ivanovic, Marija, Ravnik, Maja, Caks, Marina, Skof, Erik, Debeljak, Jerneja, Korosec, Peter, Rijavec, Matija
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245563/
https://www.ncbi.nlm.nih.gov/pubmed/35678621
http://dx.doi.org/10.2217/fon-2022-0148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245563/
https://www.ncbi.nlm.nih.gov/pubmed/35678621
http://dx.doi.org/10.2217/fon-2022-0148

Ejemplares similares